| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IBT Stock Overview
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, Germany, and internationally.
IBEX Technologies Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.45 |
| 52 Week High | CA$0.60 |
| 52 Week Low | CA$0.27 |
| Beta | 0.34 |
| 1 Month Change | 18.67% |
| 3 Month Change | -21.93% |
| 1 Year Change | 53.45% |
| 3 Year Change | 323.81% |
| 5 Year Change | 97.78% |
| Change since IPO | -89.53% |
Recent News & Updates
We Think Shareholders Will Probably Be Generous With IBEX Technologies Inc.'s (CVE:IBT) CEO Compensation
We have been pretty impressed with the performance at IBEX Technologies Inc. ( CVE:IBT ) recently and CEO Paul Baehr...
Shareholder Returns
| IBT | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 15.6% | 11.3% | -0.8% |
| 1Y | 53.4% | 10.9% | -2.0% |
Return vs Industry: IBT exceeded the Canadian Biotechs industry which returned 10.9% over the past year.
Return vs Market: IBT exceeded the Canadian Market which returned -1.9% over the past year.
Price Volatility
| IBT volatility | |
|---|---|
| IBT Average Weekly Movement | 15.7% |
| Biotechs Industry Average Movement | 12.8% |
| Market Average Movement | 10.8% |
| 10% most volatile stocks in CA Market | 19.4% |
| 10% least volatile stocks in CA Market | 4.4% |
Stable Share Price: IBT is more volatile than 75% of Canadian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: IBT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Paul Baehr | https://www.ibex.ca |
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, Germany, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research.
IBEX Technologies Fundamentals Summary
| IBT fundamental statistics | |
|---|---|
| Market Cap | CA$11.05m |
| Earnings (TTM) | CA$1.67m |
| Revenue (TTM) | CA$7.18m |
6.6x
P/E Ratio1.5x
P/S RatioIs IBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT income statement (TTM) | |
|---|---|
| Revenue | CA$7.18m |
| Cost of Revenue | CA$2.45m |
| Gross Profit | CA$4.74m |
| Other Expenses | CA$3.07m |
| Earnings | CA$1.67m |
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.067 |
| Gross Margin | 65.96% |
| Net Profit Margin | 23.23% |
| Debt/Equity Ratio | 0% |
How did IBT perform over the long term?
See historical performance and comparisonValuation
Is IBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IBT?
Other financial metrics that can be useful for relative valuation.
| What is IBT's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | CA$11.05m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.7x |
| Enterprise Value/EBITDA | 2.8x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does IBT's PE Ratio compare to its peers?
| IBT PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 11.5x | ||
MPH Medicure | 14.7x | n/a | CA$11.8m |
APC Advanced Proteome Therapeutics | 5.9x | n/a | CA$7.5m |
MBX Microbix Biosystems | 19x | 29.9% | CA$74.1m |
WLLW Willow Biosciences | 6.5x | n/a | CA$14.2m |
IBT IBEX Technologies | 6.6x | n/a | CA$11.0m |
Price-To-Earnings vs Peers: IBT is good value based on its Price-To-Earnings Ratio (6.6x) compared to the peer average (11.5x).
Price to Earnings Ratio vs Industry
How does IBT's PE Ratio compare vs other companies in the North American Biotechs Industry?
Price-To-Earnings vs Industry: IBT is good value based on its Price-To-Earnings Ratio (6.6x) compared to the North American Biotechs industry average (16.4x)
Price to Earnings Ratio vs Fair Ratio
What is IBT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 6.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IBT's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IBT (CA$0.45) is trading below our estimate of fair value (CA$10.45)
Significantly Below Fair Value: IBT is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is IBEX Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
37.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IBEX Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether IBEX Technologies is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- IBEX Technologies competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has IBEX Technologies performed over the past 5 years?
Past Performance Score
4/6Past Performance Score 4/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-6.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IBT has high quality earnings.
Growing Profit Margin: IBT's current net profit margins (23.2%) are higher than last year (19.2%).
Past Earnings Growth Analysis
Earnings Trend: IBT's earnings have declined by 6.8% per year over the past 5 years.
Accelerating Growth: IBT's earnings growth over the past year (61.1%) exceeds its 5-year average (-6.8% per year).
Earnings vs Industry: IBT earnings growth over the past year (61.1%) exceeded the Biotechs industry 47.6%.
Return on Equity
High ROE: IBT's Return on Equity (17.2%) is considered low.
Discover strong past performing companies
Financial Health
How is IBEX Technologies's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: IBT's short term assets (CA$8.0M) exceed its short term liabilities (CA$1.4M).
Long Term Liabilities: IBT's short term assets (CA$8.0M) exceed its long term liabilities (CA$1.0M).
Debt to Equity History and Analysis
Debt Level: IBT is debt free.
Reducing Debt: IBT has no debt compared to 5 years ago when its debt to equity ratio was 21%.
Debt Coverage: IBT has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: IBT has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Dividend
What is IBEX Technologies's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IBT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as IBT has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
9.8yrs
Average board tenure
CEO
Paul Baehr (79 yo)
no data
Tenure
CA$339,401
Compensation
Mr. Paul Baehr has been the Chairman and Chief Executive Officer of IBEX Technologies, Inc. since October 1995 and serves as its President. He had been Director of Acurx Pharmaceuticals, Inc. Mr. Baehr ser...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD262.18K) is above average for companies of similar size in the Canadian market ($USD185.39K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: IBT's board of directors are considered experienced (9.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
IBEX Technologies Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: IBEX Technologies Inc.
- Ticker: IBT
- Exchange: TSXV
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$11.046m
- Shares outstanding: 24.82m
- Website: https://www.ibex.ca
Location
- IBEX Technologies Inc.
- 5485 ParE Street
- Suite 100
- Montreal
- Quebec
- H4P 1P7
- Canada
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/06 00:00 |
| End of Day Share Price | 2022/08/05 00:00 |
| Earnings | 2022/04/30 |
| Annual Earnings | 2021/07/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.